Fatiabgen Bioscience Korea

[Not Yet Scheduled]
Fatiabgen focus on therapeutic markets using optimized Antibodies. Fatiabgen is using Immunotoxin platform technologies to develop treatments for AML and Pancreatic cancer. Fatiabgen also has novel Antibodies for the Treatment of Autoimmune diseases such as allergies. Fatiabgen is looking for R&D collaboration partners as well as seeking for Series A fundraising during Bio 2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
Candidate
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Fatiabgen Co., Ltd.